Departments of Internal Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Medical Genetics Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Biochem Genet. 2024 Oct;62(5):3568-3585. doi: 10.1007/s10528-023-10614-3. Epub 2023 Dec 25.
The study was designed to assess the association of ACE I/D polymorphism with the severity and prognosis of COVID-19 in the Iranian population. Hence, 186 adult patients were categorized into three clinical groups based on the severity of COVID-19: 1) Outpatients or mildly symptomatic patients as control (n = 71); 2) Hospitalized patients or severe symptomatic cases (n = 53); 3) Inpatients led to ICU/death or critically ill patients needed mechanical ventilation (n = 62). The possible association of ACE I/D polymorphism with the risk of comorbidities and serum level of C-reactive protein was evaluated in two severe cases. The results showed that the frequency of D and I alleles are 69.35% and 30.65%, respectively, in the total population. The analysis of allelic frequencies via Fisher's exact test confirmed significantly higher frequency of D allele in both severe groups than that in the mild one, 78.31% in Hospitalized patients (OR = 2.56; 95% CI 1.46 to 4.46; p-value = 0.0011) and 74.19% in Inpatients led to ICU/death (OR = 2.04; 95% CI = 1.22 to 3.43; p-value = 0.0094) compared to 58.45% in Outpatients. The results of genotype proportions displayed an association between COVID-19 severity and DD genotype. Overall, our findings in Iranian patients supported the undeniable role of the DD genotype in the intensity of the disease, comparable to other populations. Furthermore, there is no definite evidence regarding the protective effect of the I allele in our inquiry.
这项研究旨在评估 ACE I/D 多态性与伊朗人群中 COVID-19 的严重程度和预后的相关性。因此,根据 COVID-19 的严重程度,将 186 名成年患者分为三个临床组:1)门诊或症状轻微的患者作为对照组(n=71);2)住院或严重症状的患者(n=53);3)入住 ICU/死亡或需要机械通气的重症患者(n=62)。在两个重症病例中评估了 ACE I/D 多态性与合并症风险和 C-反应蛋白血清水平的可能相关性。结果表明,在总人群中,D 和 I 等位基因的频率分别为 69.35%和 30.65%。Fisher 精确检验分析等位基因频率证实,在两个重症组中 D 等位基因的频率明显高于轻症组,住院患者为 78.31%(OR=2.56;95%CI=1.46 至 4.46;p 值=0.0011),入住 ICU/死亡患者为 74.19%(OR=2.04;95%CI=1.22 至 3.43;p 值=0.0094),而门诊患者为 58.45%。基因型比例的结果显示 COVID-19 严重程度与 DD 基因型之间存在相关性。总之,我们在伊朗患者中的发现支持 DD 基因型在疾病严重程度中的不可否认的作用,与其他人群相当。此外,在我们的研究中,没有明确证据表明 I 等位基因具有保护作用。